DREADD
Designer receptors exclusively activated by designer drugs (DREADDs) are genetically engineered GPCRs that are activated by physiologically inert synthetic small molecules (designer drugs) but not their endogenous ligand. Read our DREADDs mini-review or for practical advice on using these ligands in the lab see Stability of Water-Soluble DREADD Ligands in Solution: A Technical Review and Clozapine N-Oxide (freebase) - a technical review on stability, solubility and use in the lab).
- Description:
Novel caged, fast-equilibrating glutamate receptor antagonist. Suitable for use as a synaptic probe.
Purity:>98%
-
MNI-caged-L-Glutamate (HB0423)
Description:Caged glutamate that rapidly and efficiently releases glutamate when photolysed
Purity:>98%
-
MOG (35-55) (HB5273)
Description:Myelin oligodendrocyte glycoprotein fragment. Induces experimental multiple sclerosis-like disease.
Purity:>95%
-
Monensin sodium salt (HB4882)
Description:Protein transport inhibitor. Commonly used in cytokine staining.
Purity:>98%
-
